The cancer vaccine is promising to prevent the recurrence of pancreatic colorectal tumors

An experimental cancer vaccine has proven promising to prevent certain cancers from returning.

In a phase 1 clinical trial led partly by the Integral Cancer Center of UCLA Health Jonsson, the researchers tested the vaccine (eli-002 2p) with 25 patients who had been treated for pancreatic and colorectal cancer.

All patients underwent surgery to eliminate tumors and showed “minimal residual disease signs” or DNA traces, which placed them in a high risk of recurrence, according to a UCLA press release.

The woman exceeds deadly brain cancer with cell research therapy: “truly surprising”

More than 80% of patients with pancreatic cancer experience disease recurrence after surgery, shows research, and during 40% to 50%, this happens within the first year.

For colorectal cancer, the recurrence rate is between 30% and 50% and it is more likely to occur within the first two years after surgery.

Mutations in the Kras gene are responsible for half of the colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which is directed to these mutations, was administered by a series of injections to activate an immune response in lymph nodes.

A majority (21 of 25) of patients generated “specific T cells”, indicating a stronger immune response. The researchers found that the researchers discovered that those who have higher T cell responses showed longer survival without relapse compared to those with lower responses.

The mortal brain cancer tumor of man disappears after the experimental drug trial

For three patients with colorectal cancer and three patients with pancreatic cancer, the vaccine seemed to eliminate all disease biomarkers.

Among the patients who showed the strongest immune response, a majority were still without cancer almost 20 months after receiving the vaccine.

The findings were published in Nature Medicine.

“This is an exciting breakthrough for patients with cancers driven by KRAS, particularly pancreas cancer, where recurrence after standard treatment is almost a certain and effective therapy is limited,” said the first author of the study, Zev Wainberg, MD, professor of medicine at David Geffen Medicine School in UCLA and researcher at the UCLA Health JonSon Cancer Cancer.

“We observed that patients who developed strong responses to the vaccine remained free of diseases and survived for much longer than expected.”

“The new UCLA cancer vaccine is very promising as an important tool against these cancers.”

In another finding, 67% of patients in the trial showed immune responses to “additional mutations associated with tumors”, indicating that the vaccine could be used to suppress the “broader antitumor activity.”

Click here to get the News application

According to the researchers, one of the benefits of ELI-002 2p, is that it is considered to “be in regards”, which means that it is a standardized vaccine produced in mass that does not have to be customized for each individual patient.

“This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and combat cancer driving mutations,” Wainberg said.

“It offers a promising approach to generate precise and lasting immune responses without the complexity or cost of completely personalized vaccines.”

The team has already finished registering the participants for a phase 2 study that will prove eli-002 7p, the next iteration of the vaccine that will go to a “broader set” of KRAS mutations, according to the statement.

Click here to register in our health newsletter

The study was sponsored and financed by Elicio Therapeutics, the massachusetts company that the vaccine developed.

It was carried out together with the MD Anderson Cancer Center and the Sloan Kettering Memorial Cancer Center.

Dr. Marc Siegel, News senior medical analyst, did not participate in the study, but commented that directed therapies are becoming increasingly important tools in the fight against cancer.

“Solid tumors, especially pancreatic, can be difficult to treat because they are not as mutagenic (capable of inducing or causing mutations) such as hematological neoplasms (blood cancers) or melanoma, for example, so they have no so many objectives ready for immunotherapy,” said News Digital.

For more health articles, visit www.Newsnews.com/health

“The new UCLA cancer vaccine is very promising as an important tool against these cancers, since ‘programs’ the immune system to go to these mutations and has been demonstrated in the study of nature to obtain a strong clinical response.”